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Background: Human Parvovirus B19 (B19V) is a DNA virus, transmitted through respiratory secretions, hand-to-mouth-contact, blood 
transfusion and trans-placental transfer. It causes high mortality and morbidity in pregnant women, thus contributing to poor maternal and 
child health. B19V has been neglected due to dearth of epidemiological data. The aim of this study was to determine the sero-prevalence of 
Human Parvovirus B19 antibodies among pregnant women attending antenatal clinic at Federal Teaching Hospital Ido-Ekiti, Nigeria. 
Materials and Methods: This cross-sectional study enrolled pregnant women attending Federal Teaching Hospital Ido-Ekiti from January to 
May 2019 to obtain sero-epidemiological data. One hundred and twenty-two (122) consenting pregnant women were enrolled following 
institutional ethical approval. They were administered structured questionnaire and venous blood was collected in plain tubes for serum 
extraction.  Sera samples were analyzed for IgG and IgM antibodies using the enzyme linked immunosorbent assay method. Percentages, 
median, chi-square and multivariate analysis were carried out using SPSS version 17.        
Results: The prevalence of IgG was 44.3% (54/122), IgM 41.8% (51/122), and IgG/IgM 28.7% (35/122) leaving 55.7% (68/122) of the 
population uninfected. The median age of participants was 22 (Interquartile range 18-25) years among which 36-45years had the highest 
prevalence which was not statistically significant (p=0.09 4.75). There was association between miscarriage, still birth, history of blood 
transfusion and prevalence of Human Parvovirus B19 (p<0.05).                                
Conclusion: There is a high Prevalence of B19V among pregnant women attending antenatal clinic in this study. This underscores the need 
for testing and immunization of pregnant women against B19V. 
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 Human Parvovirus B19 (B19V) is a 5.5kb single stranded, non-enveloped DNA virus, transmitted through respiratory secretions, 
hand to mouth contact, blood transfusion and trans-placental transfer (Gratacós et al., 1995). B19V has been linked as a cause of hydrops 
fetalis, intrauterine fetal death, aplastic crisis, spontaneous abortion, acute symmetric polyarthropathy and erythema infectiosum (Fifth 
disease) (Rodis et al., 1988; Gratacós et al.,1995; Simchen  et al., 2002). Its discovery was first documented in 1975 (Cossart et al., 1975).  
Human Parvovirus B19 infects erythrocyte progenitor cell stimulating apoptosis of the infected cells. Infections with this virus are 
usually asymptomatic in most patients but acute infection in patients with a high erythrocyte turnover may lead to a life-threatening aplastic 
crisis. For instance, acute congenital B19V infection in pregnancy results in non-immune hydrops fetalis (NIHF) and fetal death (Juhl and 
Henning, 2018). Fetuses at first and second trimester are most susceptible because erythroid precursor development is predominant at these 
stages (Heegaard and Brown, 2002). Of the three genotypes described worldwide, type 3 is reported to be the most commonly occurring in 
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surface of erythrocyte precursor cells, megakaryocytes, endothelia cells, placenta cells and cells at fetal myocardium (Juhl and Henning, 
2018).  
Though the prevalence of B19V among pregnant women in developing countries is not well documented, few available documents 
show a sero-prevalence of 3.3% for B19V IgM in South Africa (Mirambo et al., 2017), 32.8% in Tanzania (Mirambo et al., 2017) and 13.2% 
in Central Nigeria (Emiasegen et al., 2011). A prevalence of 24.9% for B19V IgG has been documented in South Africa, 55.0% in Tanzania 
(Mirambo et al., 2017), 27.5% in Central Nigeria (Emiasegen et al., 2011) and 20% in South-West Nigeria (Abiodun et al., 2013). 
Nigeria has a high maternal and child mortality rate which has become the main focus of the government in health care delivery in 
recent years. A number of causes for these mortalities have been listed; unfortunately, B19V despite its immense impact on child and 
maternal mortality was not enlisted (Abiodun et al., 2013). This is possibly due to paucity of epidemiological data on impact of B19V on 
pregnant women in Nigeria.  The aim of this study was to determine the prevalence and impact of Parvovirus B19V in pregnant women. 
 
Materials and Methods 
Study area 
  
This cross-sectional study was conducted between January and May 2019 at the Federal Teaching Hospital Ido-Ekiti (FETHI), Ekiti 
State, among pregnant women attending antenatal clinic.  Federal Teaching Hospital Ido-Ekiti is a referral hospital for Ado-Ekiti and some 
towns in neighboring states such as Kogi, Kwara and Osun states. It is located in Ido-Osi Local Government Area of Ekiti State Nigeria, 
latitude 7.843093, longitude 5.182314 ..\Documents\Find coordinates.docx. Laboratory analysis was carried out in the Medical Laboratories 
of the Department of Medical Laboratory Science, Afe Babalola University, Ado-Ekiti (ABUAD), Ekiti State. Ado-Ekiti is a city in 
Southwestern Nigeria and lies on latitude 7
o
 35 and 7
o




15 east of the Greenwich Meridian 
(Jameson et al., 1995). Afe Babalola University is a private institution with its campus located at Km. 8.5, Afe Babalola way, opposite 




The study population included one hundred and twenty-two pregnant women attending antenatal clinic at the Federal Teaching 
Hospital Ido-Ekiti. Subjects who consented to take part in the study were randomly selected and administered a structured questionnaire to 
collect social demographic and some health history data. 
 
Ethical Consideration  
 
Ethical approval was obtained in accordance with the Helsinki declaration from the Ethics and Research Committee, Federal 
Teaching Hospital, Ido-Ekiti, Ekiti State (Protocol No: ERC/2019/03/13/199B). The study participants were informed about the purpose of 




i. Pregnant women at exactly their 36
th
 week were excluded. 




The minimum sample size for this study was calculated using Yamane Taro’s formula (1967) for finite population (Singh and 
Masuku, 2014).  
 
Where, 
n= minimum sample size 
N= average number of pregnant women attending FTH IDO-EKITI in six months 












Sample collection  
 
 One hundred and twenty-two (122) 5ml venous blood samples were obtained from consenting participants after the administration 
of a structured questionnaire into plain tubes. Samples were centrifuged at 1000 rpm (revolution per minute) for 10 minutes. The Sera were 
harvested using Eppendorf tubes and stored at -20°C (Cheesbrough, 2006). 
 
Detection Parvovirus B19 IgG and IgM antibodies. 
 
 The sera samples were used to detect parvovirus B19V IgG and IgM antibodies using ELISA kit (Melsin Medical CO Ltd, China): 
according to manufacturer’s instructions.  
 
Test procedure for IgG/IgM   
 
 Briefly, the test procedures were as follows: The reagents provided were allowed to attain room temperature for 15 minutes before 
use. The 20X wash buffer was diluted with distilled water using a ratio of 1:20 before use. The micro-titer plate template was set up with 1 
well as blank, 2 wells as negative control and 2 wells as the positive control. 10µl of sera sample and 40µl sample diluent were dispensed 
into the respective wells except for the blank well, negative control well and positive control well. 50 µl of the negative and positive controls 
were dispensed into their wells respectively. The content was mixed by vibrating the plate gently. The microplate was covered with a sealing 
paper and incubated in a microplate incubator (MARVOTECH plate incubator, China) at 37
o
C for 60 minutes (Akele et al., 2020a). After 
incubation, the microplate was washed five times using wash buffer. 100 µl of Horseradish peroxidase enzyme (HRP) conjugate was added 
to each well except the blank; the microplate was covered with a sealing paper and also incubated in a microplate incubator at 37
o
C for 15 
minutes. After incubation, the microplate was washed five times with the diluted wash buffer in an automatic plate washer (MARVOTECH 
plate washer, China) (Akele et al., 2020b). 50 µl of substrate solution A and B were added to each well respectively and were mixed; the 
plate was covered and incubated at 37
o
C for 15 minutes. 50 µl of stop solution was added to each well and mixed. The absorbance was read 
in an ELISA reader machine (MARVOTECH ELISA reader, China) at a wavelength of 450 nm (Oluboyo et al., 2019).  
 
Interpretation of results 
 
If mean negative control O.D < 0.1 and the mean positive O.D > 0.8, the test is valid. 
Cut off = the mean O.D value of the negative control × 2.1 
Positive results: Sample O.D > Cut-off O.D 
Negative result: Sample O.D < Cut-off O.D 
 
Statistical analysis  
  
Collected data were analyzed using statistical package for social science (SPSS) version 17. Categorical variables were summarized 
as proportions while continuous variables were summarized as median with interquartile range. A multivariate regression was also conducted 




Participants had a median age of 22(IQR 18-25) years. Out of the 122 subjects, 65 (53.3%) were age group 26-35 years. 11% and 
55% of the subjects were in their first and second trimester respectively while the remaining 34% were in the third trimester. Twelve percent 
(12%) of them had a history of still birth or miscarriage. A total of 54/122 (44.3%) of subject were seropositive for B19V IgG antibodies 
while 51/122 (41.8%) were seropositive for B19V IgM antibodies leaving 68/122 (55.7%) as the susceptible population (Table 1). Thirty-five 
subjects (28.7%) were co-seropositive for both B19V IgG/IgM antibodies, while 13.1% (16/122) were seropositive for B19V IgM only (Table 
2). Prevalence of IgG and IgM was higher among the 36-45years age group (9.0% and 7.4% respectively). However, there was no 
association between age and the distribution of B19V IgG, IgM and IgG/IgM antibodies (p = 0.09, 0.97 and 0.68 respectively). 
 









OR=Odd ratio, CI=Confidence interval, X2 = Chi square, B19V=Human parvovirus B19 
 
   B19V IgG    B19V IgM 
Age Positive(%) OR (95% CI) P-Value 
 
 Positive(%) OR (95% CI) P-Value 
 
16-25 11/122(9.0) 1    13/122(10.6) 1   
26-35 32/122(26.2) 1.9 (1.1-2.7) 0.09 4.75  29/122(23.7) 2.1 (0.9-3.1)  0.97 0.61 
36-45 11/122(9.0) 1.1 (0.9-1.3)    9/122(7.4) 1.3 (0.7-1.5)   
Total 54/122(44.3)     51/122(41.8)    
13 
 
For the two vulnerable stages of pregnancy (first and second trimester), 4.1% (5/122) and 23% (28/122) respectively were 
seropositive for IgG while 3.3% (4/122) and 26.2% (32/122) respectively were seropositive for IgM antibodies leaving 44% of the 
population susceptible to B19V. There was no association between the stage of pregnancy and the distribution of B19V (p = 0.90 for IgG and 
0.32 for IgM). There was an association between history of blood transfusion, complications and the seroprevalence of B19V as those who 
had history of blood transfusion (OR 2.1 95% CI 1.7 - 2.3) p = 0.05, miscarriages (OR 2.5 95% CI 1.7-3.3) and still births (OR 2.8 95% CI 
1.7–3.1), p = 0.04 for IgG and (OR 2.1 95% CI 1.1–2.7) and (OR 1.7 95% CI 1.1–1.9) respectively, p = 0.05 for of IgM (Table 3). Parity, 
number of pregnancies, occupation and marital status hard no association with prevalence distribution of B19V (Table 3). 
 




Table 3: Multivariate analysis of factors associated with Human Parvovirus B19 (B19V) antibodies seropositivity. 
 B19V IgG B19V IgM 
Factors Positive 
(%) 





OR (95% CI) P-
Value 
 
Gestational Age        
1
st
 Trimester 5/122(4.1) 1    4/122(3.3)  1   
2
nd
 Trimester 28/122(23.0) 1.1 (0.9-2.1) 0.90 0.64 32/122(26.2) 0.9(0.7-1.5) 0.32 2.27 
3
rd
 Trimester 21/122(17.2) 1.7 (1.3-1.9)   15/122(12.3) 1.1(0.9-1.3)   
Parity        
None 23/122(18.9) 1   26/122(21.3) 1   
1-2 21/122(17.2) 1.2 (0.9-1.7) 0.77 1.13 18/122(14.8) 1.3(0.9-1.5) 0.99 0.14 
3-4 9/122(7.3) 1.5 (1.3-1.7)   6/122(5.0) 1.1(0.9-1.3)   
5-6 1/122(0.8) 1.7 (1.5-2.1)   1/122(0.8) 0.9(0.7-1.3)   
Number of pregnancy        
1-2 25/122(20.5) 1   28/122(23.0) 1   
3-4 24/122(19.7) 1.5 (1.1-1.7) 0.06 0.09 20/122(16.4) 0.9(0.7-1.1) 0.63 1.72 
5-6 5/122(4.1) 2.0 (1.7-2.3)   4/122(3.3) 0.8(0.7-1.1)   
History of Blood Transfusion        
No 53/122(43.4) 1   50/122(41.0) 1 0.05 0.76 
Yes 1/122(0.8) 2.1(1.7-2.3) 0.21 0.04 1/122(0.8) 2.5 (1.8-2.9)   
Occupation        
Student 3/122(2.4) 1   6/122(5.0) 1   
Self 
employed 
32/122(26.2) 2.1 (1.7-2.3) 0.13 5.67 30/122(24.6) 0.9(0.6-1.1) 0.14 0.99 
House wife 11/122(9.0) 1.5 (1.3-1.7)   7/122(5.7) 0.9(0.7-1.1)   
Civil servant 8/122(6.6) 1.7 (1.5-2.1)   8/122(6.6) 0.7(0.6-1.3)   
Marital Status        
Married 50/122(41) 1 0.42 1.73 45/122(36.9) 1 0.83 0.37 
Single 4/122(3.3) 0.6 (0.5-1.0)   6/122(5.0) 1.3(1.1-1.5)   
Complication History        
None 38/122(31.1) 1   41/122(33.6) 1   
Miscarriage 13/122(10.7) 2.5 (1.7-3.3) 0.04 0.85 11/122(9.0) 2.1(1.1-2.7) 0.05 2.27 
Still birth 2/122(1.6) 2.8 (1.7-3.1)   1/122(0.8) 1.7(1.1-1.9)   
Both 1/122 (0.8) 2.0 (1.5-2.3)   1/122(0.8) 1.5(1.3-2.1)   
OR=odd ratio,      CI=confidence interval,    X
2  




 B19V IgG/IgM 
Age Positive (%) OR (95% CI) P-Value 
 
16-25 8/122(6.6) 1   
26-35 20/122(16.4) 1.5 (0.9-2.1) 0.68 6.13 
36-45 7/122(5.7) 1.3 (0.9-1.7)   





The findings of this present study revealed 44.3% B19V IgG prevalence and 41.8% B19V IgM prevalence among the study 
population. The prevalence as indicated by B19V IgG is similar to the 41.5% reported in Northern Nigeria (Jegede et al., 2014), 52.5% 
reported in North Central Nigeria (Okojokwu et al., 2018) and 55% reported in Tanzania (Mirambo et al., 2017) but higher than 20% 
(Abiodun et al., 2013) reported in Southwest Nigeria. The increased prevalence from Southwest Nigeria could be related to time lag since the 
research was conducted about 10 years ago. This suggests that the prevalence of B19V has doubled over the last ten years. The incidence of 
the disease as indicated by B19V IgM was very high similar to 39.9% reported in India (Kishore et al., 2010) but higher than 13% reported in 
Central Nigeria (Emiasegen et al., 2011) and 9.5% in Southwest Nigeria. This disparity may not be unconnected to seasonal peaks variation 
and the evolving epidemiology of the virus. It has been reported that the peak period of B19V is usually late winter and spring with 75% of 
IgM-positive cases recorded between January and June (Enders et al., 2007; Crowcroft et al., 1999; Bremner et al., 1994). This present study 
was in like manner conducted between January and May, 2019. It is also possible that the year 2019 when the study was conducted coincides 
with the epidemic year of B19V. This argument is backed up by the report of Ender and colleagues (2007) which suggested that the epidemic 
cycle of B19V appears to be around 4 years with 1-2 epidemic years followed by 2 or 3 years of less frequent rates of infection. w. However, 
the B19V IgG/IgM co-prevalence which Mirambo et al., referred to as true indicator of incidence was 28.7% in this present study. The 
prevalence reported is significant because 44.3% of the population do not have antibodies against B19V as such if they get infected during a 
first or second trimester of pregnancy, they may develop complications.      
 Similar to the findings in North central Nigeria (Emiasegen et al., 2011; Okojokwu et al., 2018), the highest prevalence was 
recorded among the age group >36 years but contrary to their report, prevalence of IgM was also highest in the lower age group in this study.  
The reason for this may not be unconnected to cultural and behavioral diversity in different locations of the country. Similar to the report by 
Abiodun et al. (2013) there was no association between age, Incidence (IgM) and prevalence of B19V (IgG) recorded in this study.  
Seventy-one percent (36/51) of subjects with recent infections as indicated by the presence of IgM where still within the first or 
second trimester; a high-risk stage for B19V complication in pregnant. Prevalence of B19V increased progressively with number of parity 
while prevalence of B19V IgM decreased with increase in parity. Contrary to the findings of Okojokwu et al. (2018), we found no 
association between parity and prevalence of B19V. There was an association between history of blood transfusion and the prevalence of 
both IgG and IgM (P = 0.04 and 0.05 respectively). Based on the association recorded, IgG had an odds ratio of 2.1 (95%CI 1.7-2.3) which 
indicates that those who had B19V had a 2.1 times likelihood of haven been exposed to blood transfusion. In like manner, IgM had an odds 
ratio of 2.5 (95%CI 1.8-2.9) also implying 2.5% likelihood of haven been exposed to blood transfusion. This finding corresponds with 
previous reports (Heegaard and Brown, 2002; Ender et al., 2007) that documented an association between Blood transfusion and prevalence.  
It is hereby recommended that B19V screening be included as a criterion for blood donation and transfusion. An association was 
recorded between history of pregnancy related complications and prevalence of both IgG and IgM (P= 0.04 and 0.05 respectively). These 
complications include Miscarriages and still births. Their odds ratio suggests that women who had suffered miscarriage and still birth had 
greater than two times likelihood of have been exposed to B19V infection. This finding deferred from the report of Okojokwu et al. (2018), 
who reported no association between miscarriage, still birth and prevalence of B19V. This is probably due to sociocultural variations between 
the two study locations.  There was no association recorded between parity, number of pregnancies, occupation, marital status and 
prevalence of B19V IgG and IgM. The high incidence rate recorded within a population with a high percentage of susceptible individuals is 




In the present study, we recorded a 44.3% B19V IgG and 41.8% B19V IgM prevalence rate leaving 44.3% of the population with 
the potential of getting infected with the virus.  The findings point to a possibility of association between history of blood transfusion, history 
of complication and both prevalence and incidence of B19V. This is indicative of an urgent need for a B19V intervention plan which should 
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